Data Sheet 10_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…EC₅₀ estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC_0−3d of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”

Image 6_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…EC₅₀ estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC_0−3d of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”

Image 5_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…EC₅₀ estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC_0−3d of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”

Data Sheet 1_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…EC₅₀ estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC_0−3d of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”

Data Sheet 4_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…EC₅₀ estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC_0−3d of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”

IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule. by Tingting Wang (123983)

Discovery of Novel Substituted <i>N</i>‑(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors by Jimin Xu (2208961)

“…The preliminary mechanistic studies indicated that compounds <b>6</b> and <b>43</b> possibly target the HAdV DNA replication process, while compounds <b>46</b> and <b>47</b> suppress later steps of HAdV life cycle. Notably, among these derivatives, compound <b>15</b> showed improved anti-HAdV activity (IC₅₀ = 0.27 μM), significantly decreased cytotoxicity (CC₅₀ = 156.8 μM), and low <i>in vivo</i> toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further <i>in vivo</i> efficacy studies for the treatment of HAdV infections.…”

Surface characterization of the thermal remodeling helical plant virus by Alexander L. Ksenofontov (429873)

“…At the same time, there was a decrease in tritium label incorporation into the N- and C- terminal region (1–15 a.a., 142–158 a.a). …”

IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia. by Tingting Wang (123983)

Correlations between the OUS-DE, its subscales, quarantine moral judgement, quarantine moral behavior, and moral behavior during Christmas and New Year. by Aistė Ambrasė (22505574)

Identified MMV compounds inhibit <i>N</i>. <i>parisii</i>. by Qingyuan Huang (625246)

Concentration-response curves to leptin in endothelium-denuded rings from spontaneously hypertensive rats (SHR). by Samantha Gomart (3639661)

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis by Mei Yang (51996)

“…</p><p>Results</p><p>Serum levels of CK-18-M30, FGF-21, IL-1Ra and PEDF increased, while OPG decreased in a stepwise fashion in controls, non-NASH NAFLD patients and NASH patients (<i>P</i> < 0.01). …”

MMV1782387 inhibits microsporidia proliferation. by Qingyuan Huang (625246)

IFA disarmed capsule-mediated immune evasion. by Tingting Wang (123983)

Reduction of L O-ag production and antigenic shift to O2-antigen in by Fermin E. Guerra (6084545)

“…<p><b><i>S.</i> Paratyphi A decreases IgM binding. (</b>A) and (B) Restored <i>S.…”

Sociodemographic Characteristics of the final sample. by Aistė Ambrasė (22505574)

Standardized factor loadings for OUS-DE in the CFA (N = 378). by Aistė Ambrasė (22505574)

Sociodemographic Characteristics of Participants after Exclusions in Study 2. by Aistė Ambrasė (22505574)

Results of Confirmatory Factor Analyses (N = 378). by Aistė Ambrasė (22505574)